Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Nimbus Puts Off IPO A While Longer With $400m From Gilead

This article was originally published in Scrip

Executive Summary

Nimbus Therapeutics LLC was considering an initial public offering to fund its early-stage development programs, but with $400m up front from Gilead Sciences Inc. from the sale of its subsidiary Nimbus Apollo Inc., the company can hold off until the market is more favorable for biotechnology IPOs.